major depressive disorder

Showing 13 posts of 13 posts found.


Acadia’s pimavanserin falls short at Phase 3 in major depressive disorder

July 21, 2020
Manufacturing and Production, Research and Development Acadia Pharmaceuticals, major depressive disorder, phase 3, trial failure

Acadia Pharmaceuticals has lifted the lid on new Phase 3 for its therapy pimavanserin, revealing that the drug unfortunately failed …


Sage Therapeutics’ depression drug falls short at Phase 3

December 6, 2019
Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure

Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …


FDA fast-tracks psilocybin treatment for major depressive disorder

November 25, 2019
Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin

The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …


Lundbeck and Takeda’s depression drug approved in Japan

September 20, 2019
Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma

Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …


Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression

May 23, 2019
Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression

Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …


Allergan’s depression drug rapastinel fails to outperform placebo at Phase 3

March 7, 2019
Research and Development Allergan, FDA, depression, major depressive disorder, pharma, rapastinel

As Janssen celebrated the FDA approval of the first novel therapy for depression in three decades with Spravato, Allergan released …


Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …


FDA knocks back Alkermes’ opioid-based depression therapy over lack of evidence

February 4, 2019
Sales and Marketing Alkermes, FDA, major depressive disorder, pharma, rejection

Alkermes experimental opioid-based depression therapy ALKS 5461 has been rejected by the FDA, it has emerged, in the adjunctive treatment …


Alkermes sent reeling as FDA refuses review of depression treatment

April 3, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma

Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …

Phase III depression trial success for Alkermes

October 24, 2016
Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder

Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …

Rexulti (brexpiprazole)

FDA approves Lundbeck and Otsuka’s Rexulti for depression

July 14, 2015
Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia

Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …

Forest depression candidate struggles against placebo

March 1, 2011
Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder

An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …

AZ-Targacept depression candidate moves into phase IIb

February 9, 2011
Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder

AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …

Latest content